Reuters claims the U.S. banking giant has a budget that stretches into tens of millions of dollars 💸 cryptonews
Goldman Sachs is planning to capitalize on the bear market by swooping in to buy crypto firms at rock-bottom prices.
Goldman's head of digital assets, Mathew McDermott, told the news agency that FTX's collapse has emphasized why "more trustworthy, regulated cryptocurrency players" are needed. Although the bank is currently performing due diligence on a number of crypto firms, McDermott was tightlipped on which projects are in Goldman's crosshairs.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Goldman Sachs Plans to Invest Tens of Millions of Dollars in Crypto CompaniesGoldman Sachs might be on the lookout for cryptocurrency firms in wake of the FTX-induced crisis, according to a recent report
Baca lebih lajut »
Goldman Sachs reportedly looking to buy crypto firms after FTX collapseMathew McDermott argued that while the FTX collapse became a poster child for crypto, the technology behind crypto “continues to perform.”
Baca lebih lajut »
Goldman Sachs sees crypto investment opportunities after FTX fiasco: ReutersFinancial giant Goldman Sachs reportedly plans to spend 'tens of millions of dollars' to buy or invest in crypto firms after FTX's demise.
Baca lebih lajut »
Goldman Sachs upgrades this global tech giant, saying the stock could rise up to 90%Goldman has identified a new opportunity in electric vehicles and revealed a key stock to play it.
Baca lebih lajut »
CAF Cos., Goldman Sachs Asset Management for DFW multifamily acquisition - Dallas Business JournalCAF Funds, a subsidiary of CAF Companies, partnered with Urban Investment Group within Goldman Sachs Asset Management to acquire a portfolio of eight multifamily housing communities in Dallas-Fort Worth.
Baca lebih lajut »
Goldman Sachs says this biotech stock can double on treatment against common childhood brain tumorThe firm said positive clinical data in the first quarter could serve as a catalyst for the stock.
Baca lebih lajut »